Pearson Holds Close to Year High, Investors Eye What’s Next

Pearson Holds Close to Year High, Investors Eye What’s Next

June 7, 2026

London, June 6, 2026, 23:03 (BST)

  • Pearson added 1.4% on Friday while the FTSE 100 was flat.
  • The shares hit 1,175p, their highest in a year.
  • Markets are closed for the weekend, so attention is on Q2 trading, demand for AI and exam-contract momentum.

Pearson PLC shares climbed 1.4% in London on Friday, closing at 1,162p/1,163p, according to AJ Bell data. The education group’s stock hit 1,175p during the day, matching its one-year high, with volume at roughly 3.06 million shares.

Pearson outperformed the broader market on a slow Friday. The FTSE 100 edged up 0.07% to 10,368.05, but Reuters said the index still closed the week down as market caution lingered.

Pearson climbed 2.8% on Thursday to close at £11.44, according to MarketWatch, beating the FTSE 100’s 0.27% rise. Buyers returned ahead of the weekend despite no new company news in the last two days.

Pearson’s May trading update showed first-quarter underlying sales up 4%. Virtual Learning jumped 21%, while Enterprise Learning & Skills rose 8%. The company kept its 2026 forecast for mid-single-digit underlying sales growth and said it still targets adjusted operating profit of £640 million to £685 million.

Pearson CEO Omar Abbosh said in the update that the company has made “an encouraging start to the year” and remains confident about its momentum for 2026. Abbosh also noted the £350 million share buyback, calling it “progressing well” as Pearson continues to repurchase its own stock.

The buyback offers a bit of support for Pearson’s equity case, but investors are still watching to see if the company can keep showing that artificial intelligence is an advantage, not a risk. In a February Reuters interview, Abbosh said 80% of 2025 operating profit would come from assessments and virtual schools, which he described as “very defensible and robust.” Reuters

Pearson says its learning products, data and assessments are tied to regulated and trusted education systems, which the company claims makes them tougher for AI to disrupt. On the May earnings call, CEO Omar Abbosh told analysts about 90% of profit came from hybrid physical and digital services that are operationally complex. The rest, around 10%, came from core digital courseware—digital content used in coursework.

The company told investors it is pushing more AI skilling projects with big tech partners like Salesforce and Microsoft. Abbosh said both partners have put in “hundreds of millions of dollars” in extra revenue commitments through 2030. The contracts build over time instead of coming in immediately.

Pearson’s U.S. ADR closed up 1.7% at $15.56 on Friday. John Wiley & Sons edged up 0.18%. Scholastic fell 0.78%. Moves in the two peers were muted, suggesting Friday’s bid was focused on Pearson, not across the sector.

Pearson faces plenty of risk. The company told investors it expects Assessment & Qualifications to grow from the second quarter, but that follows a 1% drop in Q1. English testing is still open to weaker migration and less study-abroad demand in a few markets. And if there’s new evidence that cheap AI tools can take the place of paid courseware, the bull case could come under pressure fast.

No Pearson corporate events are on the calendar after the Q1 update on May 1. Now, investors will look at whether shares stay close to the 1,175p high, track if UK market sentiment picks up after a weaker week, and listen for any signals from management before interim results this summer.

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) Valuation Update Following United Imaging Collaboration and Phase 3 Trial News
    June 6, 2026, 6:41 PM EDT. Telix Pharmaceuticals (ASX:TLX) has inked a U.S.-focused collaboration with United Imaging, aiming to integrate theranostics technologies to refine cancer imaging protocols. The partnership centers on TLX101-Px in the U.S., potentially expanding to other products and markets. Following recent Phase 3 TLX591-Tx data, Telix's share price rose to A$13.31, marking a 24% return over 90 days but a nearly 48% decline over one year. Analysts value the stock at A$18.00, suggesting it is 26% undervalued. The company faces high-risk, high-reward prospects tied to revenue growth, margin improvement, and trial outcomes as it builds infrastructure and commercial foothold in molecular imaging and oncology diagnostics.